Alan Watts, Ph.D.

Director, Innovation & Partnerships, Orally Inhaled Products
Catalent, Inc.

Poster(s):

• (T1030-07-37) Development, Characterization, and In Vitro Efficacy Evaluation of an Inhalable H1B Antimicrobial Peptide Formulation for Treating Non-Small Cell Lung Cancer
  Tuesday, October 22, 2024

  10:30 AM – 11:30 AM MT